Hengeler Mueller advises UCB on strategic alliance with Wilex
12. January 2009
Hengeler Mueller advised the Belgian pharmaceutical company UCB Pharma S.A. on entering into a strategic partnership with the listed biopharmaceutical company Wilex AG, Munich. By way of in kind capital increase of Wilex AG, UCB Pharma S.A. will contribute through a subsidiary the entire world-wide preclinical oncology development portfolio into Wilex AG. In return, UCB Pharma S.A. will obtain a shareholding in Wilex AG of 13.19% in the future share capital.
The Hengeler Mueller team included partners Andreas Austmann and Carsten Schapmann (both Corporate/M&A, Düsseldorf), counsel Andrea Schlaffge (Intellectual Property, Düsseldorf) as well as associates Sebastian Lochen and Patrick H. Wilkening (both Düsseldorf).